A cell-based biological pacemaker is based on the differentiation of stem cells and the selection of a population displaying the molecular and functional properties of native sinoatrial node (SAN) cardiomyocytes. So far, such selection has been hampered by the lack of proper markers. CD166 is specifically but transiently expressed in the mouse heart tube and sinus venosus, the prospective SAN.
T he sinoatrial node (SAN) is the natural pacemaker of the heart. Pacemaker cells are specialized myocytes, lacking a stable resting potential, which at the end of an action potential generate a diastolic or pacemaker depolarization that drives the membrane potential slowly up to the threshold for firing the next action potential.
In the past 2 decades, the increasing implantation rate of electronic pacemakers has been primarily attributable to isolated sinus node dysfunction. 1 With increasing population aging, dysfunctions of the conduction tissue, which may trigger threatening arrhythmias, are expected to become more and more common.
With the advent of gene-based and cell-based therapeutic approaches, researchers have focused their efforts on the development of a biological pacemaker that is a cellular substrate able to connect to and induce ectopic spontaneous activity in the host tissue. 2, 3 Ideally, a biological pacemaker should be composed of cells identical to SAN cardiomyocytes. Cells with pacemaking properties may be generated from pluripotent stem cells (embryonic stem cells [ESCs] and induced pluripotent stem cells). [4] [5] [6] [7] Unfortunately, the high self-renewal capacity and plasticity of pluripotent stem cells, which make them interesting for regenerative purposes, represent their greatest disadvantages because these features imply a high teratogenic potential. There is evidence that in vitro cell commitment and differentiation of ESCs would eliminate the risk of teratoma formation. 5, 8 A limiting step in developing therapeutic applications using pluripotent stem cells consists in the isolation of a homogeneous population of cells with the desired phenotype. For example, we and others have shown that mouse ESCs differentiate into cardiomyocytes with the molecular and functional features of mature pacemaker cells; these cells are scarce and interspersed with other cell types. 4, 9 So far, most of the approaches used to isolate cardiomyocytes from pluripotent stem cells involved their genomic modification with reporter genes, 9, 10 which makes these cells barely suitable for future clinical applications. Alternative selection methods are hampered by the lack of specific extracellular cardiac markers exploitable for cell sorting. However, there are data showing that CD166 is specifically but transiently expressed in the developing mouse heart, including the sinus venosus, 11, 12 the region from which the SAN develops, and that CD166 can be used to enrich human ESCs in immature cardiomyocytes. 13 This evidence has led us to hypothesize that CD166 expression could represent a suitable marker to select precursors of pacemaker cardiomyocyte during a specific differentiation stage.
In this work, we have developed a protocol to isolate a population of CD166 + pacemaker precursors from differentiating murine ESCs, and we have shown that these cells develop into a spontaneously beating layer of cells, expressing many of the molecular and functional markers characterizing the mature SAN cells.
Methods
Detailed Methods are available in the Online Data Supplement.
The procedures used in this work conform to National and European directives for the care and use of laboratory animals (D.L. 116/1992; 86/609/CEE). Animal protocols were reviewed and approved by the local Institutional Review Board and by the Italian Ministry of Health.
ESC Culture and Differentiation
Mouse ESCs (D3 line, ATCC, and CGR8 line) were grown and differentiated as embryoid bodies (EBs) as previously described. 4
Flow Cytometry Sorting
For flow cytometry analysis and sorting, 6-, 8-, 10-, and 15-day-old EBs were collected, enzymatically and mechanically dissociated, and incubated with the fluorophore-conjugated antibodies following manufacturer instructions. Analyses were performed either soon after the sorting procedure or after 24 hours of cell reaggregation.
Quantitative Reverse-Transcriptase Polymerase Chain Reaction
Gene expression was quantified by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR; Line-GeneK, Bioer) using SYBER Premix Ex Taq II (Takara), 50 ng cDNA, and 500 nmol/L primers (for primers see Online Table I ). Data are expressed as 2 −ΔCt ×100. Because of the large range of values among the populations, statistical analysis was performed with the logarithm 2 −ΔCt ×100.
Electrophysiology
Spontaneous action potentials were recorded by the patch-clamp technique in current clamp mode using the whole-cell configuration. Temperature was kept at 36±1°C. Isoproterenol and acetylcholine were added to the extracellular solution at the proper concentration from stock solutions. For voltage-clamp recordings, only single cells were used. Solutions and voltage protocols were previously described. 4
Immunofluorescence and Video-Confocal Analysis
Samples were fixed in 4% paraformaldehyde, permeabilized, and incubated over night at 4°C with primary and fluorophore-conjugated secondary antibodies as previously described. 4 Confocal images were acquired using a video-confocal microscopy ViCo (Nikon).
Statistics
One-way ANOVA followed by Fisher least significant difference mean comparison or Student t test for independent populations was used as appropriate. Significance level was set at P=0.05.
Results

CD166 Is Coexpressed With HCN4 During Heart Development
So far, CD166 is the only marker also detected in the sinus venosus, the prospective SAN. 11, 12 Here, we have evaluated the expression pattern of CD166 in the developing mouse conduction system/SAN, identified as the cardiac regions expressing the pacemaker channel HCN, as previously reported. 14, 15 As shown in Figure 1 , in developing hearts of embryonic day 10.5 mouse embryos, CD166 and HCN4 signals are almost completely overlapped ( Figure 1A-1C ). At embryonic day 12.5, HCN4 and CD166 still colocalize in the region corresponding to the developing SAN ( Figure 1D -1F); however, as previously reported, 11 CD166 expression broadens and becomes more evident in ventricles ( Figure 1E ) and in several extracardiac organs and tissues (Online Figure I) . These data support the use of CD166 as a good candidate to isolate pacemaker cell precursors at early developmental stages.
CD166 Identifies Cardiac-Committed Cells in Differentiating Mouse ESCs
We performed flow cytometry analysis and sorting of cells dissociated from EBs and labeled with an anti-CD166 antibody at various differentiation time points; qRT-PCR was then used to quantify the expression of sarcomeric α-actinin to establish when CD166 specifically identifies cardiac-committed cells. Figure 2A shows representative dot plots of the population of viable cells (P1) obtained from the dissociation of EBs and the CD166-negative (CD166 − ; P2) and CD166-positive (CD166 + ; P3) subpopulations present at days 6, 8, 10, and 15 of differentiation. The CD166 + population was 1.4±1.3% at day 6 and increased to 12.1±6.4%, 20.7±8.1%, and 37.3±9.0% at days 8, 10, and 15, respectively. After cell sorting, the qRT-PCR revealed significantly higher levels of α-actinin in the CD166 + than in the CD166 − population at day 6 and day 8, whereas at days 10 and 15, α-actinin expression in CD166 + and CD166 − was similarly low, indicating the loss of cardiac specificity ( Figure 2B ). Therefore, we chose day 8 for selection of CD166 + cells to optimize the yield and cardiac specificity simultaneously.
To evaluate the purity of the sorting procedure, we compared the expression levels of CD166 in the 2 populations and in the undifferentiated ESCs; as expected, only the CD166 + population showed a high level of expression ( Figure 2C ). Other cardiac markers, such as cTnI, Mef2c, and GATA4, were significantly more expressed in CD166 + cells than in CD166 − cell population or in ESCs ( Figure 2D ). Because it is known that the cardiac differentiation potential may differ from clone to clone and among different cell lines, 16 we repeated the selection using a different ESC line (CGR8). Flow cytometry and qRT-PCR analyses on CGR8 ESCs confirmed that at day 8, α-actinin expression in CD166 + cells was 10-fold higher than in CD166 − cells (Online Figure II) , indicating that our selection procedure is effective in isolating cardiac precursors, independently from the ESCs line used.
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To better characterize the CD166 population, we performed a fluorescence-activated cell sorter analysis on cells dissociated from 8-day-old EBs to check for the expression of markers typically expressed in cardiovascular precursors (flk-1, Sca-1, and c-kit), in mesenchymal stem cells (CD44 and CD90), and in hematopoietic precursors (CD34). [17] [18] [19] [20] Representative dot plots in Figure 3 show that although flk-1, Sca-1, and c-kit are expressed in 8-day-old EBs (quartile 1), the fraction of cells coexpressing one of these markers with CD166 (quartile 2) is very low. The same is true for the mesenchymal markers CD90, whereas CD44 was expressed in a small proportion of CD166 + cells. As expected, the hematopoietic marker CD34 was not expressed at all. On average, the fractions of double-positive cells were as follows: flk-1 + /CD166 + , 0.3±0.1%; Sca-1 + /CD166 + , 0.6±0.1%; c-kit + /CD166 + , 3.7±2.8%; CD90/CD166 + , 1.0±0.8%; CD44/ CD166 + , 6.5±2.3%; and CD34/CD166 + , 0% (n=3).
We also evaluated the expression of genes whose expression is specifically associated with the endodermal, ectodermal, and noncardiac mesodermal lineages in CD166 + cells. The qRT-PCR analysis revealed that in CD166 + cells, the expression levels of the ectodermal marker synaptophysin, the endodermal marker transthyretin, and the mesodermal skeletal muscle-specific marker myoD were low (Online Figure  III) , further indicating that CD166 recognizes a specific subpopulation of cardiac precursors.
CD166 + Cells Express Typical SAN Genes
After sorting and 24 hours of reaggregation, most of the CD166 + -derived aggregates started to beat spontaneously (Online Video I) and continued to beat vigorously in culture (Online Video II) for ≤4 weeks. Spontaneous contraction was never seen in aggregates derived from CD166 − cells. We quantified the fraction of cells expressing α-actinin and HCN4 at various days after sorting (days 2, 3, and 4; Online Figure IV ). α-Actinin was expressed in 77% to 87% of the CD166 + cells and in 15% to 17% of the CD166 − cells, whereas HCN4 was expressed in 82% to 84% of the CD166 + cells and in 1% to 16% of CD166 − cells (Online Table II shows actual values).
We then used qRT-PCR to compare the mRNA levels of several genes expressed either in the embryonic and adult SAN or in ventricles with the levels found in early (just after sorting) or in late (3-4 weeks in culture) CD166 + cells ( Figure 4 ). We first analyzed the expression of the transcription factors Tbx18, Tbx3, Isl-1, and Shox2, which are important in SAN formation. [21] [22] [23] The expression of these genes was high in early CD166 + cells and, although it decreased in late cultures, remained at levels comparable with those found in the SAN and at levels significantly higher than those found in the ventricle.
We next quantified the gene expression of several proteins and ion channels essential for SAN function. 24 In CD166 + cells and SAN, most of these genes (ssTnI, HCN4, HCN1, caveolin 1.3, Cx30.2) are expressed at significantly higher levels than in the ventricle. Expression of the T-type calcium channel (CaV3.2), which is high in early CD166 + cells, decreased significantly at later stages; nevertheless, this decrease was accompanied by a slight increase of the CaV3.1 isoform, the other T-type calcium isoform expressed in the SAN; 24, 25 a similar isoform switch between CaV3.2 and CaV3.1 has been previously documented during both mouse development and mouse ESC differentiation. 26, 27 Connexin 45, an isoform found in all cardiac regions of the embryonic heart and downregulated after birth, 24, 28 was expressed at similar levels in all groups except in early CD166 + cells, where its expression was significantly higher. Finally, in CD166 + cells, we quantified the expression of typical ventricular genes, such as Nkx2.5, Kv4.2, HCN2, and Cx43, and again we found levels similar to those of the SAN rather than those of the ventricle (Figure 4 ). Taken together, these data indicate that during their in vitro maturation, CD166-selected cells display changes in the gene expression profile, which largely recapitulate that of the native SAN cells.
In a subset of experiments, we also have evaluated the expression of HCN4, HCN1, ssTnI, and Shox2 in CD166 − cells; as expected, these markers were significantly less expressed than in CD166 + cells (Online Figure V) . 
HCN and Calcium Channels Are Functional in CD166-Selected Cardiomyocytes
Because HCN channels are critical for pacemaker activity in both embryonic and adult SAN, 29, 30 and because their ectopic expression induces repetitive spontaneous activity in the ventricle, 31 we evaluated the expression of various HCN subunits at the protein level after 1 or 3 weeks in culture ( Figure 5 ). In agreement with qRT-PCR data, we found that after 1 week in culture, CD166 + cells expressed both HCN1 ( Figure 5B ) and HCN4 ( Figure 5E ) together with the cardiac markers α-actinin (α-act; Figure 5A and 5D), whereas HCN2, the main ventricular isoform, 32 could not be detected in α-act-positive cells ( Figure 5G and 5H) . Figure 5I shows a staining of rat neonatal ventricular myocytes as a positive control of HCN2 staining.
Interestingly, after 3 weeks in culture, CD166-selected cells acquired a morphology similar to that of adult SAN myocytes ( Figure 5J, 5K, 5M, and 5N ) and, like adult SAN cells, showed colocalization of HCN4 and CaV3 staining ( Figure 5L ). 33 Furthermore, like SAN, CD166-selected cells expressed negligible levels of the atrial-specific α-myosin heavy chain (Myh6) and of the ventricular-specific myosin light chain 2v (mlc2v), suggesting no progression of differentiation toward a chamber phenotype (Online Figure VI) .
The distribution of HCN4 staining in 25-day-old CD166selected cell syncytia was similar to that observed in murine SAN slices (Online Figure VII) .
Because CD166 + cells express the HCN isoforms (HCN4 and 1), typically found in the SAN, we also analyzed the I f current. CD166-selected cells display the I f current both after 1 week (Figure 6A , left) and 3 weeks in culture with a voltage dependence comparable with that of native mouse SAN cells ( Figure 6A 30 We also evaluated the contribution of the L-and T-type calcium currents (ICaL, ICaT) to spontaneous activity of CD166selected cells by superfusing the ICaT blocker Ni 2+ (50 µmol/L) and the ICaL blocker nifedipine (0.1 µmol/L) during spontaneous action potentials recordings ( Figure 6B) ; on average, the rate of Ni 2+ decreased by 17.7±2.6% (n=5) and the rate of nifedipine decreased by 16.9±6.4% (n=3); these values were not significantly different from those obtained from mouse SAN cells (Ni 2+ : 21.6±7.5, n=5; nifedipine: 16.5±2.2, n=6).
As mentioned previously, CD166-selected cardiomyocytes maintained their spontaneous activity for >3 weeks in culture; during this period, their beating rate increased ( Figure 7A ), and the increase was comparable with that of normal mouse embryonic development, 34 suggesting a certain degree of maturation.
Finally, we evaluated whether CD166-selected cardiomyocytes were competent to respond to autonomic agonist stimulation, a feature of SAN myocytes important for modulation of cardiac chronotropism. In Figure 7B , confocal images of CD166-selected cells double-stained with antiβ1-adrenergic, β2-adrenergic, or anti-M2 muscarinic (M2 acetylcholine) receptors and CaV3 or α-actinin (as indicated) are shown. In Figure 7C , spontaneous action potentials before (control) and during superfusion of the β-adrenergic agonist isoproterenol (1 μmol/L) or the muscarinic agonist acetylcholine (0.1 μmol/L) are shown. Upon isoproterenol and acetylcholine stimulation, the beating rate increased by 56.9±8.0% (n=5) and decreased by 22.9±5.4% (n=3), respectively.
HCN4 Promoter Is Active and Delineates CD166 + Cells
We also generated a clone of ESCs, stably expressing the enhanced green fluorescent protein (EGFP) under the transcriptional control of the HCN4 promoter (pHCN4-EGFP; Online Data Supplement). The pHCN4-EGFP-derived EBs displayed EGFP-positive contracting portions coexpressing CaV3 and HCN4 (Online Figure VIIIA) . As expected, when CD166 + cells were selected from pHCN4-EGFP EBs, the whole beating layer (Online Video III) showed the EGFP signal (Online Figure VIIIB ).
CD166-Selected Cells Drive the Rate of Cocultured Neonatal Ventricular Myocytes
We have then evaluated whether CD166-selected cells can function as a pacemaker; to this aim, we have used a widely used coculture system. [35] [36] [37] Rat neonatal ventricular myocytes were plated on top of spontaneously beating CD166 + cells or on top of quiescent CD166 − , or they were plated alone. After a few days, when a syncytium was formed, the spontaneous rate was calculated from recordings of action potentials. Cardiomyocytes in coculture with CD166 + cells had a mean rate of 1.7±0.19 Hz (n=5; data not shown), which is significantly higher than the rate obtained from cardiomyocytes in coculture with CD166 − (0.82±017 Hz; n=6) and from cardiomyocytes alone (0.84±0.09 Hz; n=7). These data indicate that CD166 + cells are able to electrically couple and drive an excitable substrate, thus behaving as a biological pacemaker.
CD166 + Cells Have a Low Proliferative Potential In Vitro and Are Not Teratogenic In Vivo
One of the major drawbacks of pluripotent stem cells resides in their high proliferative and differentiation potential, leading to teratoma formation. We have quantified CD166 + cell proliferation by bromodeoxyuridine staining; CD166 + cells showed a low proliferative potential at 24 hours (7.2±2.7%), a value that further decreased at 48 hours (3.8±1.8%); as expected, the bromodeoxyuridine incorporation rate of undifferentiated ESCs was high (63.5±4.9%). Furthermore CD166 + cells, unlike mES cells, failed to induce teratomas when injected in vivo in CD1 nude mice (Online Data Supplement and Online Figure IX ).
Discussion
The possibility to generate de novo a population of stem cellderived pacemaker cardiomyocytes similar, if not identical, to mature SAN cells would be highly desirable for the development of either a cell-based therapeutic approach aimed at reestablishing the proper cardiac rhythm (biological pacemaker) or as an in vitro cell/tissue model for testing cardioactive drugs. Pluripotent stem cells are particularly attractive for this aim because they can generate spontaneously beating cells with the molecular and functional features typical of SAN/pacemaker myocytes. 4, 6, 7, 38 Because pacemaker cells originating from differentiating ESCs are interspersed among other cell types, 4 their specific selection and isolation remain a major challenge.
So far, 2 markers have been found to be expressed both in the heart and in ESC-derived cardiomyocytes: CD166 (or ALCAM) [11] [12] [13] 39 and CD172a (or SIRPA). 40 The fact that SIRPA is expressed in both the fetal and the adult human heart (in both atria and ventricles), and the fact that in human ESCs SIRPA can be used to select a subpopulation enriched in cardiac troponin T-positive precursors, rules against its use as a selection marker for pacemaker precursors. Furthermore, SIRPA could not be detected in mouse heart, 40 suggesting that it does not represent an evolutionary conserved protein for cardiac development. We have selected cells expressing CD166. Although this protein is not an established cardiac marker, it is transiently but specifically expressed in the developing heart tube and sinus venosus, the prospective SAN. 11, 12 Here, we have shown that CD166-expressing cells also express HCN4 (Figure 1) , a protein that specifically delineates the SAN region during embryogenesis 14, 15, 41 and in adulthood. [42] [43] [44] [45] HCN4 is also fundamental for sinus node function because its absence is incompatible with life 29, 30 and mutations in its sequence can cause inherited rhythm disturbances. 46 Here, we show that freshly selected CD166 + cells, but not CD166 − cells, express high levels of HCN4 mRNA; at 1 day after sorting, most of the cells express the HCN4 proteins (Online Figure IV) . After 4 weeks in culture, CD166-selected cells maintain a high HCN4 expression and also assume the spindle-shaped morphology typical of SAN cells forming, cell agglomerates like those of native SAN ( Figure 5J-5N and Online Figure VI) . CD166 + cells also express high levels of Tbx18, Shox2, Tbx3, and Isl-1, which are known to characterize the pool of mesodermal progenitors that separate early during cardiogenesis 15 to create the sinus venosus and then the SAN. Isl-1 also identifies a population of HCN4-expressing myocytes in both the adult murine and human SAN, but it is not expressed in the working myocardium. 47 After 3 weeks in culture, the expression level of these genes is still comparable with that found in the SAN, and is higher than levels found in the ventricle. Thus, our data show that CD166 represents an optimal marker for specifically selecting SAN precursors.
CD166-based selection has been previously used to isolate cardiovascular precursors from yolk sac. 12 At embryonic day 8.5, yolk sac-derived CD166 + cells create both endothelial and cardiac cells; however, if CD166 + cells are also selected for flk-1, only the CD166 + /flk-1 − population formed cardiomyocytes. 12 In agreement with this evidence, our data show a negligible coexpression of CD166 and flk-1.
However, other data show that ESC-derived flk-1 + cardiac precursors also express c-kit and sca-1, 17, 48 and that a subpopulation of ESC-derived flk-1 + cardiac precursors selected by sca-1 formed α-myosin heavy chain-positive contracting aggregates. 49 CD166 + cardiac precursors do not express significant levels of either flk-1 or Sca-1 and express very low levels of c-kit ( Figure 3 ). Whether this means that our CD166 + cells represent a different population or a different stage of the same population of precursors, it remains to be elucidated.
Previously, Rust et al 13 have shown that CD166 selection of differentiating human ESCs results in a population enriched in cells defined as embryonic cardiomyocytes on the basis of ion channels and structural protein expression. We have instead found that mouse ESC-derived CD166 + cells represent a population specifically committed to become SAN myocytes, as indicated by the expression of specific genes ( Figure 4 ) and proteins ( Figure 5 ) and by the electrophysiological properties typical of native adult SAN cells ( Figure 6 ).
Differences between our data and those of Rust et al 13 could arise from the different species used and, more likely, as a consequence of the different isolation protocols. For example, they isolated cells when CD166 expression peaked; we instead selected cells when the difference in α-sarcomeric actinin expression between CD166 + and CD166 − cells was maximal. Other important differences concern the cell proliferation potential of CD166-selected cells. They found a proliferation rate of ≈20% to 30%, whereas our CD166-sorted cells have a much lower proliferation rate (<4% at 48 hours from sorting). Moreover, their cells maintain high CD166 expression for ≥2 weeks, whereas in our cells CD166 expression decreased significantly (Online Figure VIIIA) , as expected during cardiomyocytes maturation. 11 Previous attempts to generate pacemaker/SAN myocytes from ESCs have used either a cell-engineering 9 or a pharmacological approach, 5,50 but neither one resulted in a homogeneous population. Morikawa et al 9 generated mouse ESCs expressing the EGFP under the transcriptional control of the HCN4 gene promoter. Contracting areas of these engineered EBs expressed EGFP, HCN4, and other cardiac proteins; however, when EGFP + cells were sorted, the majority did not show spontaneous action potentials but instead expressed the neuronal marker nestin, 9 which is in line with the fact that neuronal cells also express HCN4 channels. 14 Pharmacological treatment of differentiating ESCs either with 1-ethyl-2-benzimidazolinone or with suramin increased the fraction of sinus node-like cell population by 6-fold and 3-fold, respectively; however, these treatments did not prevent contamination by other cell lineages. 5, 50 In addition to the gene expression pattern, our CD166selected cardiomyocytes also display the functional properties peculiar to the SAN cardiomyocytes. The main function of SAN myocytes is to spontaneously generate action potentials and to modulate cardiac rhythm to account for changes in oxygen demand. CD166-selected cardiomyocytes form a synchronously beating syncytium (Online Videos II and III), which fires repetitive and regular action potentials. It is interesting to note that CD166-selected cardiomyocytes, like embryonic hearts, 34 increase their beating frequency with time, reaching a rate similar to that previously reported for dissociated adult mouse SAN myocytes. 30, 51 The similarity between CD166-derived syncytia and mature SAN is further validated by the presence of functional β-adrenergic and cholinergic pathways (Figure 7) that physiologically modulate the response to autonomic stimulation and by the electrophysiological features analyzed. In particular, our data clearly show that the kinetic properties of I f and the effect on rate exerted by the blockade of calcium channels are the same in freshly isolated sinoatrial myocytes and CD166-selected cells.
Finally, it is important to note that a major concern regarding the use of pluripotent cells relates to their ability to easily generate teratomas in vivo, unless they are committed or differentiated before injection. 8 Based on the low proliferation potential, the lack of expression of pluripotency-related genes, and the failure to induce teratomas when injected in CD1 nude mice, CD166 + cells represent a safe substrate.
Study Limitation
Despite our CD166-selected cells forming a spontaneously beating syncytium and being able to electrically connect to and pace a monolayer of ventricular myocytes in vitro, their abilities to engraft within the heart and to drive it at physiological rates remain to be addressed. Similarly, although heart development is quite conserved in mammals, the possibility of translating the present protocol to human-induced pluripotent stem cells, even though CD166 expression has been reported in the human heart and in human ESC-derived cardiomyocytes and induced pluripotent stem cells-derived cardiomyocytes, remains to be elucidated.
Conclusions
In conclusion, we have demonstrated that it is possible to specifically recognize and select mesodermal precursors expressing several transcription factors characterizing those cells that will originate the sinus node in the embryo. 21, 22 Thus, we can speculate that once these precursor are isolated from other lineages of the EBs, this condition favors a high level of expression of transcription factors, such as Tbx18, Shox2, and Tbx3, preventing the switch-on of gene programs leading to the working myocardium. 22, 23 Thus, the CD166-selected cells maintain the molecular features necessary to develop into fully functional SAN cardiomyocytes. This finding, when applied to human pluripotent stem cells, could pave the path for the development of a cell-based biological pacemaker useful for clinical and in vitro pharmacological applications.
